Microscopic image of numerous elongated, oval-shaped Schistosoma mansoni eggs stained blue.
Impact Investment

Invest in a Malaria-Free World

Join Landcent and MissionInvest in accelerating the fight against diseases of poverty, starting with malaria, through impact investment.

Get in touch
The Problem

Malaria Cases Continue to Rise

Malaria remains one of the world's most urgent and persistent health challenges:

• 282M+ cases in 2024
• 1,600+ deaths every day
• 95% of cases concentrated in Africa
• $12B annual economic burden in Africa

Line chart showing malaria cases in millions rising from 230 million in 2016 to nearly 280 million in 2024.
Who We Are

Landcent & MissionInvest

Landcent

Landcent develops and delivers impactful solutions to prevent, diagnose and treat diseases of poverty, addressing both local realities and systemic barriers to health.

With 15+ years of R&D experience and over $23 million invested in building a portfolio of impactful solutions, Landcent is entering a pivotal phase, moving from development to large-scale commercialization. The company has 10 products in its pipeline, with 7 expected to be market-ready by mid-2027 (including 3 already in-market). Landcent expects to reach break-even by 2028, with projected annual revenue exceeding $72 million by 2030.

Learn more about Landcent
Landcent logo

MissionInvest

Founded in 2020, MissionInvest USA is a 501c3 non-profit organization based in Houston, Texas. MissionInvest is a Dutch organization in origin, with 25 years of expertise in philanthropic and impact investments.

From 2023 to 2025, MissionInvest (Netherlands) successfully raised close to $10M in catalytic capital for Landcent.

Learn more about MissionInvest USALearn more about MissionInvest Netherlands
"MissionInvest Netherlands has championed Landcent’s commitment to eliminate diseases of poverty by attracting critical mission-aligned capital and advisors. When it came to raising a new round, we made sure to have MissionInvest lead the efforts in their typical diligent and thorough manner."

Arun Prabhu Stanley
Founder & Executive Chairman
Landcent Europe

Product Highlight

Neonet®

Neonet® is dual Active Ingredient (AI) Insecticide-Treated Net (ITN) designed to fight insecticideresistance; highly effective in killing mosquitoes transmitting malaria.

• Progressing to final regulatory trials
• 6th–7th supplier in a $350M+ donor market
• Cost advantage

Hand behind a white mesh fabric with a hexagonal pattern, visible against a light background.
The Impact

Landcent working to protect 46+ million people from malaria by 2030

Landcent’s prevention portfolio is expected to protect more than 46 million people from malaria by 2030. The primary Sustainable Development Goals (SDGs) addressed are SDG 1 (No Poverty), SDG 3 (Good Health and Well-being), and SDG 17 (Partnerships for the Goals).

Read more here
Doctor using stethoscope on young girl while her mother holds her in outdoor setting.

Philanthropic Capital Investment Option

Intrested in putting your capital to work for impact?

Through MissionInvest USA, Landcent partners with Impact Foundation to offer a simple, transparent way to deploy philanthropic capital.

Ask us how you can get involved!

Contact Us
Let's Connect

Interested in investing in Landcent?

Wim Hasselman
Founder, MissionInvest
whasselman@mission-invest.com

Justin Hays
CEO, Landcent
justin.hays@landcent.nl

Whether you would like to discuss the investment opportunity, learn more about our products or request any investor materials, we would be pleased to hear from you.